Zhaoqing Fan

Zhaoqing Fan


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Cancer
Verified
Journal Article
Closed access
QZQijun Zheng
Qijun Zheng
HYHuicui Yan
Huicui Yan
YHYingjian He
Yingjian He
JWJiwei Wang
Jiwei Wang
NZNan Zhang
Nan Zhang
ZFZhaoqing Fan
Zhaoqing Fan

11 November 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
XCXue Chen
Xue Chen
XLXiaoting Li
Xiaoting Li
ZFZhaoqing Fan
Zhaoqing Fan
JLJin-Feng Li
Jin-Feng Li
YXYuntao Xie
Yuntao Xie
TOTao Ouyang
Tao Ouyang
Background The status of axillary lymph nodes (ALNs) is one of the important factors in decision‐making for breast cancer treatment. Physical examination (PE) has long been the main, or even the only, means of clinical staging for ALNs in breast cancer. However, the sensitivity and accuracy of PE remains unsatisfactory. The results from this study suggest that axillary ultrasonography (US) should replace PE as a standard method for the clinical staging of ALNs in breast cancer. Methods Consecutive and nonselective breast cancer patients treated between September 2018 and November 2018 in our center were enrolled in the study. Comparisons of ALN results between PE/US and pathological results were conducted and the difference in sensitivity, specificity and accuracy between PE and US were tested by McNemar chi‐square test. Results A total of 123 patients were enrolled into the study. Their ages ranged from 28 to 76 years with a median age of 53 ± 10. There were 83 ALN positive cases and 40 ALN negative cases confirmed pathologically. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of PE and US were 54.2%, 90.0%, 65.9%, 91.8%, 48.7% versus 86.8%, 72.5%, 82.1%, 86.8%, 72.5%, respectively. The sensitivity and accuracy of US was significantly higher than that of PE (P = 0.004 and P = 0.002). Conclusion The results of this study demonstrated that US is superior in evaluating ALNs when compared with PE and that US should replace PE as the standard method for the clinical staging of ALNs in breast cancer.

28 March 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYin Liu
Yin Liu
YXYe Xu
Ye Xu
TOTao Ouyang
Tao Ouyang
JLJin-feng Li
Jin-feng Li
TWTianfeng Wang
Tianfeng Wang
YXYuntao Xie
Yuntao Xie
Our previous study suggested that the recurrent CHEK2 H371Y mutation is a novel pathogenic mutation that confers an increased risk of breast cancer. The purpose of this study was to investigate whether breast cancer patients with CHEK2 H371Y mutation were more likely to respond to neoadjuvant chemotherapy. We screened a cohort of 2334 Chinese women with operable primary breast cancer who received a neoadjuvant chemotherapy regimen for CHEK2 H371Y germline mutations. Pathologic complete response (pCR) was defined as the absence of tumor cells in the breast after the completion of neoadjuvant chemotherapy. Thirty-nine patients (1.7%) with CHEK2 H371Y germline mutation were identified in this cohort of 2334 patients. CHEK2 H371Y mutation carriers had a significantly higher pCR rate than non-carriers (33.3% versus 19.5%, P = 0.031) in the entire study population, and CHEK2 H371Y mutation-positive status remained an independent favorable predictor of pCR in a multivariate analysis (odds ratio [OR] = 3.01; 95% confidence interval [CI]: 1.34- 6.78, P = 0.008). CHEK2 H371Y carriers had a slightly worse distant recurrence-free survival than non-carriers (adjusted hazard ratio [HR] =1.24, 95% CI: 0.59-2.63). CHEK2 H371Y mutation carriers are more likely to respond to neoadjuvant chemotherapy than are non-carriers.

21 December 2022 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
CGChongshan Gu
Chongshan Gu
XCXue Chen
Xue Chen
LWLize Wang
Lize Wang
YHYingjian He
Yingjian He
TOTao Ouyang
Tao Ouyang
ZFZhaoqing Fan
Zhaoqing Fan
Background: Whether sentinel lymph node biopsy should be performed in patients ≥70 years old with early-stage invasive breast cancer is controversial. We examined the effect of sentinel lymph node biopsy on the treatment and outcomes in this population. Materials and Methods: In this retrospective study, patients aged ≥70 years who were treated for invasive breast cancer with sentinel lymph node biopsy followed by mastectomy or lumpectomy between 2010 and 2019 were identified from our database. Patients were compared according to sentinel lymph node status. Outcomes were analyzed using the Kaplan–Meier method and Cox multivariate analysis. Results: Of the 376 patients enrolled in this study, 311 (82.7%) were sentinel lymph node-negative and 65 (17.3%) were sentinel lymph node-positive. The median follow-up duration for all patients was 70 months. Systemic treatment and radiation were similar between sentinel lymph node-negative and -positive groups. Disease-free survival, distant disease-free survival, breast cancer-specific survival, overall survival were not significantly different between groups (88.2% vs 87.6%, 96.7% vs 94.8%, 96.2% vs 93.6%, and 93.5% vs 90.0%, respectively). Sentinel lymph node status, tumor size, chemotherapy, endocrine therapy, and adjuvant radiation were included in Cox multivariate analysis. None of the variables were found to significantly affect disease-free survival, distant disease-free survival, breast cancer-specific survival, and overall survival. Conclusions: Our analysis indicated that sentinel lymph node status may not affect systemic treatment decisions or survival in patients aged ≥70 years with breast cancer.

19 January 2022 in Cancer Communications
Verified
Journal Article
Open access
PDF file
XWXin Wang
Xin Wang
KFKexin Feng
Kexin Feng
WWWenyan Wang
Wenyan Wang
XMXiangzhi Meng
Xiangzhi Meng
JLJiaqi Liu
Jiaqi Liu
XWXiang Wang
Xiang Wang
Click on the article title to read more.

9 June 2025 in The Breast
Verified
Journal Article
Open access
YXYirong Xiang
Yirong Xiang
JTJian Tie
Jian Tie
SZSiyuan Zhang
Siyuan Zhang
CSChen Shi
Chen Shi
CGChangkuo Guo
Changkuo Guo
WWWei-Hu Wang
Wei-Hu Wang
This study developed an explainable machine learning model for baseline internal mammary lymph node metastasis (IMNM) in breast cancer patients. This study included three cohorts: a derivation cohort (n = 1997) from Peking University Cancer Hospital, a temporal testing cohort (n = 633) from the same center, and a SEER cohort (n = 51,420). Multiple machine learning strategies were conducted: Least Absolute Shrinkage and Selection Operator (LASSO), Boruta, backward stepwise regression, and best subset for feature selection, and logistic regression (LR), support vector machines (SVM), k-nearest neighbors (KNN), and extreme gradient boosting (XGBoost) for model construction. The best-performing model was validated across internal and temporal testing cohorts. Shapley Additive Explanations (SHAP) analysis was conducted to improve interpretability. Six clinical features (clinical N stage, size, stage, classification, grade and location) were used to construct the final predictive model with SVM. The model achieved robust performance, with AUCs of 0·811 (0·790-0·843), 0.806 (0·760-0·857) and 0·864 (0·830-0·926) in the training, internal testing and temporal testing cohort, respectively. High-risk patients exhibited significantly worse outcomes with DFS (HR 2·776, 95 % CI: 1·897-4·064, p < 0·001) and OS (HR of 1·962, 95 % CI: 1·853-2·077, p < 0·001). An online prediction tool was established that allows users to input key clinical variables and obtain model-predicted probabilities along with SHAP-based explanations. This validated and explainable machine learning model offers a practical tool for early risk stratification, aiding clinicians in appropriate baseline imaging selection and adjuvant treatment planning.